Sepantronium Bromide (PC-002/YM155)
Myc-dependent tumors (e.g., high-grade B-cell lymphoma, Burkitt lymphoma with Myc rearrangement)
Key Facts
About Cothera Bioscience
Cothera Bioscience is a private, clinical-stage oncology biotech leveraging a platform centered on synthetic lethality and protein degradation to drug historically challenging targets like Myc. Its pipeline features two lead assets: sepantronium bromide (PC-002), a first-in-class DUB inhibitor in Phase 2 for Myc-driven lymphomas, and zotiraciclib (ZTR), an oral CDK9/PIM inhibitor with Fast Track designation for IDH-mutant high-grade glioma. Founded by veterans from Crown Bioscience and Silicon Valley, the company is pre-revenue, advancing its programs through clinical trials and strategic collaborations, including with the National Cancer Institute.
View full company profile